Ketamine For Chronic Pain: Risks And Benefits - PubMed

Home » What Is Ketamines Infusion For Pain » Ketamine For Chronic Pain: Risks And Benefits - PubMed

Maybe your like

Full text links CiteDisplay options Display options Format AbstractPubMedPMID

Abstract

The anaesthetic ketamine is used to treat various chronic pain syndromes, especially those that have a neuropathic component. Low dose ketamine produces strong analgesia in neuropathic pain states, presumably by inhibition of the N-methyl-D-aspartate receptor although other mechanisms are possibly involved, including enhancement of descending inhibition and anti-inflammatory effects at central sites. Current data on short term infusions indicate that ketamine produces potent analgesia during administration only, while three studies on the effect of prolonged infusion (4-14 days) show long-term analgesic effects up to 3 months following infusion. The side effects of ketamine noted in clinical studies include psychedelic symptoms (hallucinations, memory defects, panic attacks), nausea/vomiting, somnolence, cardiovascular stimulation and, in a minority of patients, hepatoxicity. The recreational use of ketamine is increasing and comes with a variety of additional risks ranging from bladder and renal complications to persistent psychotypical behaviour and memory defects. Blind extrapolation of these risks to clinical patients is difficult because of the variable, high and recurrent exposure to the drug in ketamine abusers and the high frequency of abuse of other illicit substances in this population. In clinical settings, ketamine is well tolerated, especially when benzodiazepines are used to tame the psychotropic side effects. Irrespective, close monitoring of patients receiving ketamine is mandatory, particularly aimed at CNS, haemodynamic, renal and hepatic symptoms as well as abuse. Further research is required to assess whether the benefits outweigh the risks and costs. Until definite proof is obtained ketamine administration should be restricted to patients with therapy-resistant severe neuropathic pain.

Keywords: NMDA receptor antagonist; chronic pain; ketamine; ketamine abuse; neuropathic pain; pain.

PubMed Disclaimer

Figures

Figure 1

Figure 1

A-C. Resting state MRI areas…

Figure 1

A-C. Resting state MRI areas of connectivity in the brain during low dose…

Figure 1 A-C. Resting state MRI areas of connectivity in the brain during low dose ketamine exposure in healthy volunteers relative to network of interest 1 (NOI1). The data are linked to the antinociceptive properties of the drug by assessment of pain relief to a heat pain stimulus and incorporation of pain relief as regressor in the statistical model. The statistical map gives the variations in connectivity explained by ketamine (yellow) and by pain relief (green). These green areas indicate that pain relief is associated with increased connectivity in the anterior cingulate cortex (ACC), orbitofrontal cortex, brain stem and amygdala in relation to the network of interest (in blue). These regions are involved in pain sensing, pain processing and activation of descending inhibition of pain. (Adapted from , with permission)
Figure 2

Figure 2

Psychotropic effects observed during intravenous…

Figure 2

Psychotropic effects observed during intravenous low-dose ketamine (•) and placebo (○) treatment. A)…

Figure 2 Psychotropic effects observed during intravenous low-dose ketamine (•) and placebo (○) treatment. A) Drug high, B) changes in internal perception (inner feelings that do not correspond with reality) and C) changes in external perception (misperceptions of an external stimulus or change in the awareness of the surroundings). NRS, numerical rating scale. (Adapted from , with permission)
See this image and copyright information in PMC

Comment in

  • Prolonged ketamine infusion as a therapy for complex regional pain syndrome: synergism with antagonism? Pickering AE, McCabe CS. Pickering AE, et al. Br J Clin Pharmacol. 2014 Feb;77(2):233-8. doi: 10.1111/bcp.12157. Br J Clin Pharmacol. 2014. PMID: 23701138 Free PMC article. No abstract available.

References

    1. Okie S. A flood of opioids, a rising tide of deaths. N Engl J Med. 2010;363:1981–1985. - PubMed
    1. Dworkin RH, O'Connor AB, Audette J, Baron R, Gourlay GK, Haanpää ML, Kent JL, Krane EJ, Lebel AA, Levy RM, Mackey SC, Mayer J, Miaskowski C, Raja SN, Rice AS, Schmader KE, Stacey B, Stanos S, Treede RD, Turk DC, Walco GA, Wells CD. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc. 2010;85:S3–14. - PMC - PubMed
    1. Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain. 2005;118:289–305. - PubMed
    1. Sigtermans MJ, van Hilten JJ, Bauer MCR, Arbous MS, Marinus J, Sarton EY, Dahan A. Ketamine produces effective and long-term pain relief in patients with Complex Regional Pain Syndrome Type 1. Pain. 2009;145:304–311. - PubMed
    1. Eide PK, Jorum E, Stubhaug A, Bremnes J, Breivik H. Relief of post-herpetic neuralgia with the N-methyl-D-aspartic acid receptor antagonist ketamine: a double-blind, cross-over comparisonwith morphine and placebo. Pain. 1994;58:347–354. - PubMed
Show all 88 references

Publication types

  • Review Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search

MeSH terms

  • Analgesics / administration & dosage Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Analgesics / adverse effects Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Analgesics / therapeutic use* Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Anesthetics, Dissociative / adverse effects Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Anesthetics, Dissociative / therapeutic use Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Animals Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Chronic Pain / drug therapy* Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Drug Monitoring / methods Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Humans Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Ketamine / administration & dosage Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Ketamine / adverse effects Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Ketamine / therapeutic use* Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Neuralgia / drug therapy Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Receptors, N-Methyl-D-Aspartate / antagonists & inhibitors Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Severity of Illness Index Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Substance-Related Disorders / epidemiology Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Time Factors Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search

Substances

  • Analgesics Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Anesthetics, Dissociative Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Receptors, N-Methyl-D-Aspartate Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Ketamine Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search

LinkOut - more resources

  • Full Text Sources

    • Europe PubMed Central
    • Ovid Technologies, Inc.
    • PubMed Central
    • Wiley

  • Other Literature Sources

    • The Lens - Patent Citations Database
    • scite Smart Citations

  • Medical

    • ClinicalTrials.gov
    • MedlinePlus Health Information

Tag » What Is Ketamines Infusion For Pain